Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M -1.21%91 EV-to-OCF is 17.42 as of Sep. 04, 2026, which is 10% below its 10-year median of 19.44. GuruFocus rates LTS:0R2M with a GF Score™ of 91/100 and a GF Value™ of $888.36 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,408 Biotechnology companies, Regeneron Pharmaceuticals ranks worse than 87.57% on this metric.
The historical rank and industry rank for Regeneron Pharmaceuticals's EV-to-OCF or its related term are showing as below:
LTS:0R2M'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.08 Med: 19.44 Max: 48.05
Current: 17.42
During the past 13 years, the highest EV-to-OCF of Regeneron Pharmaceuticals was 48.05. The lowest was 7.08. And the median was 19.44.
LTS:0R2M's EV-to-OCF is ranked worse than 87.57% of 1408
companies
in the Biotechnology industry
Industry Median: -3.68
vs LTS:0R2M: 17.42
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regeneron Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Regeneron Pharmaceuticals's share price for today is $840.95.
Regeneron Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Regeneron Pharmaceuticals EV-to-OCF Related Terms
Regeneron Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regeneron Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's EV-to-OCF falls into.
Regeneron Pharmaceuticals's current Enterprise Value is $81,551 Mil.
Regeneron Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,681 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (LTS:0R2M) has a EV-to-OCF of 17.42 as of Sep. 04, 2026. This is 10% below median its historical median of 19.44. Over the past decade, Regeneron Pharmaceuticals' EV-to-OCF has ranged from 7.08 to 48.05. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #1233 out of 1408 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Regeneron Pharmaceuticals' EV-to-OCF too high?
Regeneron Pharmaceuticals' current EV-to-OCF of 17.42 is 10% below median its 10-year median of 19.44. Over the past 10 years, this metric has ranged from a low of 7.08 to a high of 48.05. Based on the distribution chart, Regeneron Pharmaceuticals ranks #1233 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' EV-to-OCF compare to MRNA and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #1233 out of 1408 companies for EV-to-OCF. This places Regeneron Pharmaceuticals in the lower half of its industry. Historically, Regeneron Pharmaceuticals' own EV-to-OCF has ranged from 7.08 to 48.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Regeneron Pharmaceuticals's current EV-to-OCF is 17.42, which is 10% below median its own 10-year median of 19.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Fairly Valued. The stock's GF Value™ is $888.36, compared to a current price of $840.95 — trading 5.3% below its estimated fair value. The current EV-to-OCF is 17.42, which is 10% below median its 10-year median of 19.44. Regeneron Pharmaceuticals' overall GF Score™ is 91/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current EV-to-OCF is 17.42 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $840.95 is trading 5.3% below its estimated GF Value™ of $888.36.
GuruFocus considers Regeneron Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0R2M:
EV-to-OCF: 17.42 (10% below median its 10-year median of 19.44)
GF Value™: $888.36 vs. price of $840.95 (5.3% below fair value)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
91GF Score
Get the complete analysis for LTS:0R2M
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
